GT Biopharma has completed dosing patients in a Phase l trial of GTP-004 for the treatment of myasthenia gravis symptoms.

The trial is designed to demonstrate that gastro-intestinal (GI) side-effects can be safely reduced with GTP-004.

It has enrolled five healthy volunteers, who have received single increasing oral doses of pyridostigmine ranging from 30mg to 120mg administered once-daily in the morning.

When the enrolled subjects reached first intolerable dose (FID1) as determined by protocol criteria, upward dose escalation of pyridostigmine was stopped and the subjects were washed-out for two to seven days.

Subjects who reached FID level were administered with daily increasing doses of pyridostigmine in combination with ondansetron.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results showed that GTP-004 allows the safe and well-tolerated administration of doses of pyridostigmine.

“The data provide evidence of the ability of GTP-004 to avoid the GI side-effects of administering pyridostigmine alone and offer hope to all those suffering from myasthenic syndromes.”

In addition, three subjects in two males and one female reached FID with pyridostigmine alone.

GT Biopharma CEO Dr Kathleen Clarence-Smith said: “These are early results, but the data provide evidence of the ability of GTP-004 to avoid the GI side-effects of administering pyridostigmine alone and offer hope to all those suffering from myasthenic syndromes.

“We expect to be in a position to begin a Phase ll clinical trial in patients in the second half of 2018.”

GT Biopharma further noted that its GTP-004 solution combines pyridostigmine with ondansetron.

It intends to lessen the GI side-effects of pyridostigmine alone, providing the potential for a fully efficacious dose of pyridostigmine to be safely used.